BRAF and melanoma: A therapeutic strategy based on dual inhibition of the MAPK pathway through targeting BRAF and MEK proteins with BRAF inhibitors (e.g., dabrafenib or vemurafenib) in combination with MEK inhibitors (e.g., trametinib or cobimetinib) has significantly improved progression-free survival (PFS) and overall survival (OS) in melanoma patients harboring activating BRAF mutations [3].